EUVIMEDEUVIMED entdecken
Crossref

Diagnostic performance evaluation of the PowerChek Respiratory Virus Panels 1, 2, 3, and 4 for the detection of respiratory viruses, including SARS-CoV-2

Kyeong Seon Ryu, Jae Hyeon Park, Jee-Soo Lee, Moon-Woo Seong

Annals of Clinical Microbiology · 20.03.2026 · 29 (1) · 5-5

DOI: 10.5145/acm.2026.29.1.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Microbiology, online erschienen am 20.03.2026. Verfasst von Kyeong Seon Ryu und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The accurate laboratory-based detection of respiratory viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is essential for effective patient management and infection control in the post–coronavirus disease 2019 era. In this study, the performance of the PowerChek Respiratory Virus Panels 1–4 assay (Kogene Biotech) in detecting non-SARS-CoV-2 respiratory viruses and SARS-CoV-2 was compared with those of two established commercial assays.

Methods

Residual clinical respiratory specimens collected between December 2023 and February 2024 were retested using the PowerChek assay. Of the 129 specimens retested, 80 had tested positive for 14 non-SARS-CoV-2 respiratory virus targets in the Allplex Respiratory Panels 1–3 assay (Seegene) and 49 had been tested using the Alinity m SARS-CoV-2 assay (Abbott; 20 positive and 29 negative for SARS-CoV-2). Agreement, Cohen’s kappa, and discordant results were assessed.

Results

For the 14 non-SARS-CoV-2 respiratory virus targets, the virus-specific overall percent agreement (OPA) ranged from 95.0% to 100%, the positive percent agreement (PPA) ranged from 66.7% to 100%, and the negative percent agreement (NPA) ranged from 96.0% to 100%, with kappa values of 0.64–1.00. Lower agreements were observed for human coronavirus OC43 and influenza A virus. For SARS-CoV-2 detection, the OPA was 98.0% (PPA, 95.0%; NPA, 100%; kappa, 0.96).

Conclusion

The detection performance of the PowerChek assay was comparable to those of the established assays for most respiratory virus targets, with lower agreement observed for some targets. These features support its practical utility for the routine multiplex molecular detection of respiratory viruses, including SARS-CoV-2.

Zitieren

APA

Ryu, K. S., Park, J. H., Lee, J., & Seong, M. (2026). Diagnostic performance evaluation of the PowerChek Respiratory Virus Panels 1, 2, 3, and 4 for the detection of respiratory viruses, including SARS-CoV-2. Annals of Clinical Microbiology, 29(1), 5-5. https://doi.org/10.5145/acm.2026.29.1.5

Vancouver

Ryu KS, Park JH, Lee J, Seong M. Diagnostic performance evaluation of the PowerChek Respiratory Virus Panels 1, 2, 3, and 4 for the detection of respiratory viruses, including SARS-CoV-2. Annals of Clinical Microbiology. 2026;29(1):5-5. doi:10.5145/acm.2026.29.1.5

BibTeX
@article{Ryu2026,
  author = {Ryu, Kyeong Seon and Park, Jae Hyeon and Lee, Jee-Soo and Seong, Moon-Woo},
  title = {Diagnostic performance evaluation of the PowerChek Respiratory Virus Panels 1, 2, 3, and 4 for the detection of respiratory viruses, including SARS-CoV-2},
  journal = {Annals of Clinical Microbiology},
  year = {2026},
  volume = {29},
  number = {1},
  pages = {5--5},
  doi = {10.5145/acm.2026.29.1.5}
}
Kostenlos starten →